newsfilter
← Latest News
Business Wire·

Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

Consistent evidence supports benefits of complete revascularization on LVEF, heart failure symptoms Abiomed (NASDAQ:ABMD) announces the results of the Restore EF study demonstrate Impella-supported high-risk percutaneous coronary intervention (PCI) l